The cost-utility of intravenous magnesium sulfate for treating asthma exacerbations in children

Vista sencilla de ítem
dc.contributor.authorBuendia, Jefferson Antonio
dc.contributor.authorAcuña-Cordero, Ranniery
dc.contributor.authorRodríguez-Martínez, Carlos E.
dc.date.accessioned2020-09-02T21:46:39Z
dc.date.available2020-09-02T21:46:39Z
dc.description.abstractenglishIntroduction Although evidence supports the use of intravenous magnesium sulfate (MS) in asthma exacerbations, MS continues to be considered a second‐line drug for managing pediatric asthma exacerbations. This study aimed to evaluate the cost‐utility of MS in asthma exacerbations. Methods We used a decision tree model to estimate the cost‐utility of MS compared to treatment without MS (control group) in children with asthma exacerbations. Cost data were obtained from a retrospective study from tertiary centers in Rionegro, Colombia, while utilities were collected from the literature. Probabilistic sensitivity analysis was carried out using the Monte Carlo technique with a simulation of a hypothetical cohort of 10 000 patients to generate expected cost utilities with 95% confidence intervals. We used a cost‐effectiveness acceptability curve to evaluate the uncertainty surrounding the cost‐utility of MS. Results The model showed that MS had a lower total cost than the control group (US $1149 vs US $1598 average cost per patient) and higher quality‐adjusted life years (0.60 vs 0.52 average per patient), showing dominance. The probability that MS provides a more cost‐effective use of resources compared with standard therapy exceeds 99% for all willingness‐to‐pay thresholds. Conclusion Intravenous MS was less expensive and more effective than treatment without intravenous MS in children with asthma exacerbations. Our study provides evidence that should be used by decision‐makers to improve clinical practice guidelines and should be replicated to validate its results in other middle‐income countries.eng
dc.format.mimetypeapplication/pdf
dc.identifier.doihttps://doi.org/10.1002/ppul.25024
dc.identifier.instnameinstname:Universidad El Bosquespa
dc.identifier.reponamereponame:Repositorio Institucional Universidad El Bosquespa
dc.identifier.repourlhttps://repositorio.unbosque.edu.co
dc.identifier.urihttps://hdl.handle.net/20.500.12495/3933
dc.language.isoeng
dc.publisherWiley-Blackwellspa
dc.relation.ispartofseriesPediatric Pulmonology, 1099-0496, 2020spa
dc.relation.urihttps://onlinelibrary.wiley.com/doi/abs/10.1002/ppul.25024
dc.rights.accessrightshttps://purl.org/coar/access_right/c_abf2
dc.rights.accessrightsinfo:eu-repo/semantics/openAccess
dc.rights.accessrightsAcceso abierto
dc.rights.creativecommons2020-08-13
dc.rights.localAcceso abiertospa
dc.subject.keywordsHealth carespa
dc.subject.keywordsHealth economicsspa
dc.subject.keywordsPublic healthspa
dc.titleThe cost-utility of intravenous magnesium sulfate for treating asthma exacerbations in childrenspa
dc.title.translatedThe cost-utility of intravenous magnesium sulfate for treating asthma exacerbations in childrenspa
dc.type.coarhttps://purl.org/coar/resource_type/c_6501
dc.type.driverinfo:eu-repo/semantics/article
dc.type.hasversioninfo:eu-repo/semantics/publishedVersion
dc.type.localArtículo de revista

Archivos

Bloque de licencias
Mostrando 1 - 1 de 1
No hay miniatura disponible
Nombre:
license.txt
Tamaño:
1.71 KB
Formato:
Item-specific license agreed upon to submission
Descripción:
Descargar

Colecciones

Artículos